EBV vaccine research has achieved a significant milestone with the development of human monoclonal antibodies. Scientists from the Fred Hutch Cancer Center successfully tested these antibodies in mice with human immune systems. Consequently, this breakthrough addresses a virus that infects nearly 95% of people worldwide.
Progress in EBV Vaccine Research
The study focused on two viral surface proteins, gp350 and gp42. While gp350 helps the virus bind to cell receptors, gp42 facilitates cell entry. Researchers developed ten monoclonal antibodies to target these specific proteins. One antibody against gp42 completely prevented infection in humanized mice. Therefore, this discovery offers hope for high-risk patients, such as transplant recipients.
Emerging Risks: Microplastics and Cancer
Besides viral threats, new environmental factors are emerging in oncology. A recent study identified microplastics in 90% of prostate cancer samples. Furthermore, these plastic fragments appeared at higher levels within tumors compared to healthy tissue. Specifically, tumors contained 2.5 times more plastic than noncancerous prostate samples. This evidence suggests that microplastic exposure might be a potential risk factor for malignancy.
Frequently Asked Questions
Q1: How do the new antibodies prevent Epstein-Barr virus infection?
The antibodies target proteins like gp42 and gp350 to block the virus from binding to and entering human cells.
Q2: Did researchers link microplastics directly to prostate cancer?
While the study identified higher plastic levels in tumors, researchers still require more evidence to confirm a causal link.
References
- Scientists develop promising antibodies to prevent Epstein-Barr infection – ETHealthworld
- Chhan, C. B., et al. (2026). Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42. Cell Reports Medicine.
- Loeb, S., et al. (2026). Microplastics Found in 90 Percent of Prostate Cancer Samples. ASCO Genitourinary Cancers Symposium.
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.